Pfizer Inc. (NYSE:PFE) announced Wednesday an exclusive licensing agreement with Starna Therapeutics worth up to $2.63 billion in upfront and milestone payments, plus royalties.
The agreement expands Pfizer’s inflammation and immunology pipeline while strengthening its presence in next-generation cell therapies.
Deal Terms and Financial Details
Starna will receive an upfront payment of $330 million. The biotechnology company is also eligible for up to $2.3 billion in development and commercial milestone payments, plus royalties on net sales of approved products.
Under the agreement, Pfizer gains exclusive rights outside Greater China to develop, manufacture and commercialize three early-stage CAR-T cell therapy programs targeting autoimmune diseases.
Pfizer will lead clinical development outside Greater China. It also plans to manufacture finished drug products for initial clinical trials at its U.S. facilities.
Additionally, Pfizer will retain exclusive control over commercialization outside Greater China, with options to expand its rights into the region.
Expanding Cell Therapy Capabilities
The agreement gives Pfizer access to Starna’s proprietary in vivo CAR-T technology for applications in inflammation, immunology and oncology.
CAR-T therapy involves reprogramming immune cells to target specific disease-causing cells. The in vivo approach aims to perform this process directly inside the patient’s body.
Pfizer also secured options to exclusively license compounds developed through a separate research collaboration.
However, the three initial programs remain at the pre-investigational new drug application stage, meaning they are still in early development.
Strengthening Pfizer’s RNA Medicine Portfolio
Michael Vincent, Pfizer’s chief inflammation and immunology officer, said the technology could address the needs of autoimmune disease patients who have limited treatment options.
He highlighted Pfizer’s global experience in developing and manufacturing RNA-based medicines as a key advantage in advancing Starna’s programs.
Meanwhile, Starna CEO Rongkuan Hu said the company’s targeted lipid nanoparticle delivery platform and RNA technology provide a foundation for developing in vivo CAR-T therapies.
The partnership combines Pfizer’s expertise in immunology, drug development and commercialization with Starna’s RNA delivery technology. It also opens opportunities to develop new treatments for autoimmune diseases and cancer.
PFE Price Action: Pfizer shares were down 1.28% at $28.10 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
